Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "Formulations"

487 News Found

Lupin partners with Shaan to raise awareness on mental health
Healthcare | November 10, 2021

Lupin partners with Shaan to raise awareness on mental health

Shaan’s hit song `Tanha Dil Tanha Safar relaunched


Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin
Biotech | November 05, 2021

Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin

The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent


Venus Remedies H1 net profit rises 315%
News | November 03, 2021

Venus Remedies H1 net profit rises 315%

Venus Remedies has reported consolidated financial results for the period ended September 30, 2021


Glenmark launches novel fixed-dose combination for diabetes
Drug Approval | October 26, 2021

Glenmark launches novel fixed-dose combination for diabetes

It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination


Biocon Q2FY22 in line with estimates, better margins: ICICI Direct
News | October 25, 2021

Biocon Q2FY22 in line with estimates, better margins: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Domestic growth to the fore as US weakness persists: ICICI Direct
News | October 19, 2021

Domestic growth to the fore as US weakness persists: ICICI Direct

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report


Shilpa Medicare raises over Rs. 297 crore through preferential allotment
News | October 15, 2021

Shilpa Medicare raises over Rs. 297 crore through preferential allotment

Equity raise to finance growth and investments in the biological space


Expect normal quarter in Q2FY22: Emkay
News | October 15, 2021

Expect normal quarter in Q2FY22: Emkay

Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report


PCI Pharma Services acquires LSNE for its CDMO business
News | October 13, 2021

PCI Pharma Services acquires LSNE for its CDMO business

Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle


IPM growth led by Covid  driven products to taper off in Q2FY22: Nirmal Bang
News | October 06, 2021

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report